步长制药
(603858)
| 流通市值：153.12亿 | | | 总市值：153.12亿 |
| 流通股本：10.55亿 | | | 总股本：10.55亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 5,003,092,046.35 | 2,579,013,525.28 | 11,875,013,010.12 | 8,468,581,319.22 |
| 营业总成本 | 4,365,535,951.93 | 2,180,656,976.18 | 10,600,810,736.07 | 7,531,602,618.43 |
| 其他经营收益 | | | | |
| 营业利润 | 613,875,787.85 | 385,825,789.41 | 566,108,735.55 | 1,049,101,858.29 |
| 利润总额 | 602,870,999.32 | 382,581,420.15 | 533,955,471.71 | 1,020,579,043.56 |
| 净利润 | 461,825,547.8 | 303,102,749.18 | 192,297,553.48 | 791,128,418.9 |
| 每股收益 | | | | |
| 其他综合收益 | -679,343.46 | 6,756,134.75 | -53,165,050.17 | -50,998.71 |
| 综合收益总额 | 461,146,204.34 | 309,858,883.93 | 139,132,503.31 | 791,077,420.19 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 8,011,791,906.15 | 8,501,163,928.16 | 7,893,509,677.84 | 7,928,743,680.18 |
| 非流动资产: | | | | |
| 非流动资产合计 | 11,151,319,451.51 | 11,139,311,468.96 | 11,351,200,100.42 | 11,641,561,802.31 |
| 资产总计 | 19,163,111,357.66 | 19,640,475,397.12 | 19,244,709,778.26 | 19,570,305,482.49 |
| 流动负债: | | | | |
| 流动负债合计 | 6,690,238,470.54 | 6,994,918,855.25 | 7,170,975,372.54 | 6,921,900,560.79 |
| 非流动负债: | | | | |
| 非流动负债合计 | 3,059,419,815.18 | 3,024,790,966.75 | 2,637,300,346.16 | 2,576,324,969.38 |
| 负债合计 | 9,749,658,285.72 | 10,019,709,822 | 9,808,275,718.7 | 9,498,225,530.17 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 10,058,811,909.24 | 10,220,639,423.46 | 10,011,881,835.8 | 10,572,989,443.73 |
| 股东权益合计 | 9,413,453,071.94 | 9,620,765,575.12 | 9,436,434,059.56 | 10,072,079,952.32 |
| 负债和股东权益合计 | 19,163,111,357.66 | 19,640,475,397.12 | 19,244,709,778.26 | 19,570,305,482.49 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 5,252,973,874.19 | 2,460,370,159.3 | 11,254,947,390.5 | 8,278,581,398.17 |
| 经营活动现金流出小计 | 4,955,341,003.67 | 2,495,817,427.98 | 10,097,160,315.65 | 7,463,489,485.46 |
| 经营活动产生的现金流量净额 | 297,632,870.52 | -35,447,268.68 | 1,157,787,074.85 | 815,091,912.71 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 110,717,578.66 | 108,126,446.75 | 111,392,249.83 | 18,662,900.29 |
| 投资活动现金流出小计 | 202,048,692.01 | 257,761,825.84 | 153,424,399.41 | 372,621,486.54 |
| 投资活动产生的现金流量净额 | -91,331,113.35 | -149,635,379.09 | -42,032,149.58 | -353,958,586.25 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 2,060,387,213.45 | 1,389,459,339.06 | 1,968,847,557.24 | 1,503,116,701.92 |
| 筹资活动现金流出小计 | 1,941,123,149.33 | 819,983,487.67 | 2,697,009,912.71 | 1,915,541,189.25 |
| 筹资活动产生的现金流量净额 | 119,264,064.12 | 569,475,851.39 | -728,162,355.47 | -412,424,487.33 |
| 汇率变动对现金及现金等价物的影响 | -12,695.62 | -81,778.15 | -75,142.76 | -8,302.28 |
| 现金及现金等价物净增加额 | 325,553,125.67 | 384,311,425.47 | 387,517,427.04 | 48,700,536.85 |
| 期末现金及现金等价物余额 | 1,530,603,526.47 | 1,589,596,144.75 | 1,205,050,400.8 | 866,233,510.61 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | 325,553,125.67 | - | 387,517,427.04 | - |